Patents by Inventor Thierry Dervieux

Thierry Dervieux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11885812
    Abstract: Provided herein are methods of diagnosing and monitoring disease activity and response to treatment in patients having systemic lupus erythematosus using panels of biomarkers, such as at least one biomarker selected from the group consisting of B-lymphocyte-bound C4d, erythrocyte-bound C4d, platelet-bound C4d, and erythrocyte complement receptor type 1, and one further biomarker selected from the group consisting of anti-MCV antibody and anti-nuclear antibody.
    Type: Grant
    Filed: September 13, 2023
    Date of Patent: January 30, 2024
    Assignee: EXAGEN INC.
    Inventors: Thierry Dervieux, Cole Harris
  • Publication number: 20240003902
    Abstract: Provided herein are methods of diagnosing and monitoring disease activity and response to treatment in patients having systemic lupus erythematosus using panels of biomarkers, such as at least one biomarker selected from the group consisting of B-lymphocyte-bound C4d, erythrocyte-bound C4d, platelet-bound C4d, and erythrocyte complement receptor type 1, and one further biomarker selected from the group consisting of anti-MCV antibody and anti-nuclear antibody.
    Type: Application
    Filed: September 13, 2023
    Publication date: January 4, 2024
    Inventors: Thierry Dervieux, Cole Harris
  • Patent number: 11761965
    Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: September 19, 2023
    Assignee: EXAGEN INC.
    Inventors: Thierry Dervieux, Cole Harris
  • Publication number: 20230228768
    Abstract: Methods and reagents for diagnosing, prognosing, and treating systemic lupus erythematosus (SLE) are disclosed, involving calculating an SLE risk score for a subject based on a level of each of an erythrocyte C4d (EC4d) marker, a B-cell C4d (BC4d) marker, anti-nuclear antibodies (ANA), and optional rule-out markers.
    Type: Application
    Filed: March 23, 2023
    Publication date: July 20, 2023
    Inventors: Thierry Dervieux, Derren Barken
  • Publication number: 20230194548
    Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.
    Type: Application
    Filed: February 15, 2023
    Publication date: June 22, 2023
    Applicant: Exagen Inc.
    Inventors: Thierry Dervieux, Cole Harris
  • Publication number: 20230194553
    Abstract: Methods and reagents for diagnosing, prognosing, and treating systemic lupus erythematosus (SLE) are disclosed, involving calculating an SLE risk score for a subject based on a level of each of an erythrocyte C4d (EC4d) marker, a B-cell C4d (BC4d) marker, anti-nuclear antibodies (ANA), and optional rule-out markers.
    Type: Application
    Filed: November 23, 2022
    Publication date: June 22, 2023
    Inventors: Thierry Dervieux, Derren Barken
  • Patent number: 11531033
    Abstract: Methods and reagents for diagnosing, prognosing, and treating systemic lupus erythematosus (SLE) are disclosed, involving calculating an SLE risk score for a subject based on a level of each of an erythrocyte C4d (EC4d) marker, a B-cell C4d (BC4d) marker, antinuclear antibodies (ANA), anti-Smith antibodies (anti-Sm) and optional rule-out markers (SS-B/La, Scl-70, Jo-1, CENP, MCV).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 20, 2022
    Assignee: Exagen Inc.
    Inventors: Thierry Dervieux, Derren Barken
  • Publication number: 20220299510
    Abstract: Provided herein are methods for the diagnosis, prognosis, and treatment of thrombosis in subject having or suspected of having systemic lupus erythematosus including determination of a level of platelet-bound complement C4d, C3 level, and one or both of a level of antiphosphatidyl serine/prothrombin complex and/or lupus anticoagulant.
    Type: Application
    Filed: August 12, 2020
    Publication date: September 22, 2022
    Inventor: Thierry Dervieux
  • Publication number: 20220276259
    Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.
    Type: Application
    Filed: May 12, 2022
    Publication date: September 1, 2022
    Inventors: Thierry Dervieux, Cole Harris
  • Patent number: 11360099
    Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: June 14, 2022
    Assignee: EXAGEN INC.
    Inventors: Thierry Dervieux, Cole Harris
  • Publication number: 20210220389
    Abstract: Provided herein are methods for the diagnosis, prognosis, and treatment of thrombosis in subject having or suspected of having systemic lupus erythematosus including determination of a level of platelet-bound complement C4d, C3 level, and one or both of a level of antiphosphatidyl serine/prothrombin complex and/or lupus anticoagulant.
    Type: Application
    Filed: April 5, 2021
    Publication date: July 22, 2021
    Inventor: Thierry Dervieux
  • Publication number: 20190025326
    Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 24, 2019
    Inventors: Thierry Dervieux, Cole Harris
  • Patent number: 10132813
    Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: November 20, 2018
    Assignee: Exagen Diagnostics, Inc.
    Inventors: Thierry Dervieux, Cole Harris
  • Patent number: 9822391
    Abstract: The present invention provides methods for assessing efficacy of a methotrexate (MTX) dosing regimen in a patient.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: November 21, 2017
    Inventor: Thierry Dervieux
  • Publication number: 20160138074
    Abstract: The present invention provides methods for assessing efficacy of a methotrexate (MTX) dosing regimen in a patient.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 19, 2016
    Inventor: Thierry Dervieux
  • Patent number: 9261509
    Abstract: The present invention provides methods for assessing efficacy of a methotrexate (MTX) dosing regimen in a patient.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: February 16, 2016
    Inventor: Thierry Dervieux
  • Publication number: 20150369824
    Abstract: Methods and reagents for diagnosing, prognosing, and treating systemic lupus erythematosus (SLE) are disclosed, involving calculating an SLE risk score for a subject based on a level of each of an erythrocyte C4d (EC4d) marker, a B-cell C4d (BC4d) marker, antinuclear antibodies (ANA), anti-Smith antibodies (anti-Sm) and optional rule-out markers (SS-B/La, Scl-70, Jo-1, CENP, MCV).
    Type: Application
    Filed: March 13, 2014
    Publication date: December 24, 2015
    Applicant: EXAGEN DIAGNOSTICS, INC.
    Inventors: Thierry DERVIEUX, Derren BARKEN
  • Publication number: 20130309698
    Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.
    Type: Application
    Filed: February 10, 2012
    Publication date: November 21, 2013
    Applicant: EXAGEN DIAGNOSTICS, INC.
    Inventors: Thierry Dervieux, Cole Harris
  • Publication number: 20130230865
    Abstract: The present invention provides methods for assessing efficacy of a methotrexate (MTX) dosing regimen in a patient.
    Type: Application
    Filed: September 13, 2011
    Publication date: September 5, 2013
    Inventor: Thierry Dervieux
  • Publication number: 20130131072
    Abstract: The present invention provides methods for optimizing clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. The methods of the present invention may further comprise determining the level of at least one long-chain methotrexate polyglutamate (MTXPG) in a sample obtained from the individual. The present invention also provides methods for generating a pharmacogenetic index for predicting clinical responsiveness to chemotherapy in an individual through genotypic analysts of polymorphisms in at least one gene. In addition, the present invention provides methods for optimizing therapeutic efficacy of chemotherapy in an individual by calculating the level of at least one long-chain MTXPG in a sample obtained from the individual.
    Type: Application
    Filed: January 25, 2013
    Publication date: May 23, 2013
    Inventors: Thierry Dervieux, Michael Walsh